ADC Therapeutics (ADCT) Deferred Taxes (2023)
ADC Therapeutics (ADCT) posted quarterly Deferred Taxes of $42.9 million for Q4 2023, up 7514.19% on a QoQ basis from -$578000.0 in Q3 2023.
ADC Therapeutics (ADCT) Deferred Taxes (2023) Analysis & Trends
ADC Therapeutics (ADCT) has reported Deferred Taxes for 1 consecutive years, with $42.9 million the latest figure, recorded in Q4 2023.
- Quarterly Deferred Taxes changed N/A year-over-year to $42.9 million in Q4 2023, while the trailing twelve-month figure through Sep 2024 was $42.9 million (changed N/A YoY) and the FY2023 annual result came in at $37.1 million, up 2388.96% from the prior year.
- Deferred Taxes improved to $42.9 million in Q4 2023 per ADCT's latest filing, from -$578000.0 in the prior quarter.
- Over the last five years, Deferred Taxes for ADCT reached as high as $42.9 million in Q4 2023 and fell as low as -$5.1 million in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -188,883.60 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -65.30 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 96.00 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | ADC Therapeutics | 189.60 Mn | -41.41 Mn | 17.38 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 42.85 Mn |
| Sep 30, 2023 | -578,000.00 |
| Jun 30, 2023 | -5.10 Mn |
| Mar 31, 2023 | -69,000.00 |